Zepbound leads to more weight loss than Wegovy, new study finds
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Eli Lilly’s Zepbound outperforms Novo's Wegovy for weight loss in head-to-head trial
Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise in Lilly's shares.
Eli Lilly says its weight loss drug Zepbound outperformed Wegovy in a study
Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head randomized controlled trial.
Eli Lilly's Zepbound defeats Novo Nordisk's Wegovy in head-to-head weight loss trial
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market and patients wondered which company’s products were more effective, there | Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.
Eli Lilly says Zepbound beat rival weight loss drug Wegovy in head-to-head study
Zepbound is the “superior” choice for people looking to shed a few pounds, at least compared to Novo Nordisk’s (NVO) Wegovy, according to Eli Lilly (LLY).
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients on obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Lilly Says Zepbound Provided 47% Higher Relative Weight Loss Compared To Wegovy In SURMOUNT-5 Study
Wednesday announced encouraging topline results from the SURMOUNT-5 phase 3b study of Zepbound in adults with obesity. The study was designed to evaluate Zepbound compared with Novo Nordisk's Wegovy in adults with obesity with at least one of the following comorbidities: hypertension,
Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal
Eli Lilly & Co. Inc.’s stock rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound achieved an average weight loss of 20.
Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s drug.
This weight loss drug helped people shed more pounds than Wegovy, new trial results show
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical trial, Lilly said in a release Wednesday.
Mounjaro Lawsuits (2024 Update)
Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...
Ozempic and similar medications are revolutionising weight loss, with far-reaching economic effects
The rise of weight loss drugs is not only changing individual lives, but also reshaping large sections of the economy.
Jefferson Public Radio2d
Dizzy after one drink? Social drinkers on obesity drugs lose the taste for alcohol
A new study finds people who take weight-loss drugs also cut back on alcohol consumption. Researchers think the drugs could ...
Why the New Weight Loss Drugs Don't Work for Some People
Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% ...
10 Famous People Who Actually Admitted To Using Ozempic And 9 Who Flat-Out Denied It
According to WebMD, "Ozempic and Wegovy are different brand names for the same injectable drug, semaglutide." Wegovy is ...
devdiscourse1d
Novo Nordisk Races to Launch Wegovy in India Amid Competitive Pressures
Novo Nordisk is working to accelerate the launch of its weight-loss drug Wegovy in India, concerned about lagging behind Eli ...
Jim Gaffigan And Whoopi Goldberg Bond Over Taking Weight Loss Drugs On ‘The View’: “I Don’t Know Why People Are Afraid To Admit It”
Gaffigan recently revealed to People that he lost 50 pounds since starting Mounjaro, which is a drug used to treat type 2 ...
Eli Lilly’s Growth Driven by Strong Prescription Trends for Mounjaro and Zepbound
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...